Frontiers in Microbiology (Feb 2024)

Combinations of the azaquinazoline anti-Wolbachia agent, AWZ1066S, with benzimidazole anthelmintics synergise to mediate sub-seven-day sterilising and curative efficacies in experimental models of filariasis

  • Shrilakshmi Hegde,
  • Amy E. Marriott,
  • Nicolas Pionnier,
  • Andrew Steven,
  • Christina Bulman,
  • Emma Gunderson,
  • Ian Vogel,
  • Marianne Koschel,
  • Alexandra Ehrens,
  • Sara Lustigman,
  • Denis Voronin,
  • Nancy Tricoche,
  • Achim Hoerauf,
  • Achim Hoerauf,
  • Marc P. Hübner,
  • Marc P. Hübner,
  • Judy Sakanari,
  • Ghaith Aljayyoussi,
  • Fabian Gusovsky,
  • Jessica Dagley,
  • David W. Hong,
  • Paul O'Neill,
  • Steven A. Ward,
  • Mark J. Taylor,
  • Joseph D. Turner

DOI
https://doi.org/10.3389/fmicb.2024.1346068
Journal volume & issue
Vol. 15

Abstract

Read online

Lymphatic filariasis and onchocerciasis are two major neglected tropical diseases that are responsible for causing severe disability in 50 million people worldwide, whilst veterinary filariasis (heartworm) is a potentially lethal parasitic infection of companion animals. There is an urgent need for safe, short-course curative (macrofilaricidal) drugs to eliminate these debilitating parasite infections. We investigated combination treatments of the novel anti-Wolbachia azaquinazoline small molecule, AWZ1066S, with benzimidazole drugs (albendazole or oxfendazole) in up to four different rodent filariasis infection models: Brugia malayi—CB.17 SCID mice, B. malayi—Mongolian gerbils, B. pahangi—Mongolian gerbils, and Litomosoides sigmodontis—Mongolian gerbils. Combination treatments synergised to elicit threshold (>90%) Wolbachia depletion from female worms in 5 days of treatment, using 2-fold lower dose-exposures of AWZ1066S than monotherapy. Short-course lowered dose AWZ1066S-albendazole combination treatments also delivered partial adulticidal activities and/or long-lasting inhibition of embryogenesis, resulting in complete transmission blockade in B. pahangi and L. sigmodontis gerbil models. We determined that short-course AWZ1066S-albendazole co-treatment significantly augmented the depletion of Wolbachia populations within both germline and hypodermal tissues of B. malayi female worms and in hypodermal tissues in male worms, indicating that anti-Wolbachia synergy is not limited to targeting female embryonic tissues. Our data provides pre-clinical proof-of-concept that sub-seven-day combinations of rapid-acting novel anti-Wolbachia agents with benzimidazole anthelmintics are a promising curative and transmission-blocking drug treatment strategy for filarial diseases of medical and veterinary importance.

Keywords